Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -36.64% is 43% below its 1-year average of -25.70%, near the low end of its 1-year range (-36.64%–-18.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 35.33% below its 12-month average of -27.07%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -36.64%.
RETURN ON EQUITY (ROE)
-36.64%
RETURN ON EQUITY (ROE) AVG TTM
-27.07%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.33%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+12.78%
vs the sector median at left
Sionna Therapeutics, Inc.
Market Cap
$214.46M
Return on Equity (ROE)
-36.64%
TTM Avg
-27.07%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.24M
Return on Equity (ROE)
19.38%
TTM Avg
20.63%
3Y Avg
-8.44%
5Y Avg
-40.10%
Market Cap
$215.07M
Return on Equity (ROE)
21.24%
TTM Avg
17.52%
3Y Avg
32.51%
5Y Avg
46.01%
Market Cap
$216.91M
Return on Equity (ROE)
-45.23%
TTM Avg
-120.85%
3Y Avg
-88.04%
5Y Avg
-69.68%
Market Cap
$210.98M
Return on Equity (ROE)
-106.27%
TTM Avg
-100.08%
3Y Avg
-64.49%
5Y Avg
-52.22%
Market Cap
$218.30M
Return on Equity (ROE)
-31.70%
TTM Avg
-2.04%
3Y Avg
-21.96%
5Y Avg
-21.56%
Market Cap
$210.41M
Return on Equity (ROE)
-71.02%
TTM Avg
-15.82%
3Y Avg
-19.73%
5Y Avg
-5.35%
Market Cap
$209.91M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$208.31M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $214.46M | -36.64% | -27.07% | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 19.38% | 20.63% | -8.44% | -40.10% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 21.24% | 17.52% | 32.51% | 46.01% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -45.23% | -120.85% | -88.04% | -69.68% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -106.27% | -100.08% | -64.49% | -52.22% |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | -31.70% | -2.04% | -21.96% | -21.56% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -71.02% | -15.82% | -19.73% | -5.35% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 39.66% | 4.24% | -15.88% | -20.06% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | -65.59% | -45.72% | -59.51% | -49.73% |
ROE
-36.6%
ROA
-34.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -36.64% |
| 2026-03-31 | -29.69% |
| 2025-12-31 | -24.53% |
| 2025-09-30 | -21.97% |
| 2025-06-30 | -22.54% |
| 2025-03-31 | -18.85% |
